OBJECTIVES: Patients surviving retinopathy-positive cerebral malaria (CM) are at high risk for the development of epilepsy, developmental disabilities, and behavioral abnormalities. We aimed to establish whether retinopathy-negative CM is also a risk factor for these outcomes. METHODS: Between 2005 and 2007, survivors of CM and concurrently hospitalized controls in Blantyre, Malawi, were followed to assess the development of neurologic abnormalities. At discharge and every 3 months thereafter, incident cases of epilepsy and developmental disabilities were ascertained using screening questionnaires and confirmatory neurologic examinations. Incident cases of epilepsy and developmental disabilities were compared in retinopathy-negative CM survivors to controls and retinopathy-positive CM survivors. RESULTS: Thirty-five retinopathy-negative CM survivors were enrolled. Their neurologic outcomes were compared to 132 retinopathy-positive CM survivors and 272 controls. Compared to survivors of retinopathy-positive CM, children without malaria retinopathy have an equal odds of adverse neurologic outcome (odds ratio [OR] = 1.0, 95% confidence interval [CI] 0.4-2.2). Eleven of 35 survivors of retinopathy-negative CM had at least 1 adverse neurologic outcome compared to 2 of 272 controls (OR 61.9, 95% CI 13.0-295.5). In retinopathy-negative CM survivors, a Blantyre Coma Scale score ≤ 1 on admission was associated with an adverse outcome. CONCLUSIONS: Compared with controls, children surviving either retinopathy-negative or -positive CM are at similar high risk for adverse neurologic outcomes. Studies to evaluate preventive and therapeutic strategies in children with both retinopathy-negative and -positive CM are needed to improve mortality, morbidity, or both.
OBJECTIVES:Patients surviving retinopathy-positive cerebral malaria (CM) are at high risk for the development of epilepsy, developmental disabilities, and behavioral abnormalities. We aimed to establish whether retinopathy-negative CM is also a risk factor for these outcomes. METHODS: Between 2005 and 2007, survivors of CM and concurrently hospitalized controls in Blantyre, Malawi, were followed to assess the development of neurologic abnormalities. At discharge and every 3 months thereafter, incident cases of epilepsy and developmental disabilities were ascertained using screening questionnaires and confirmatory neurologic examinations. Incident cases of epilepsy and developmental disabilities were compared in retinopathy-negative CM survivors to controls and retinopathy-positive CM survivors. RESULTS: Thirty-five retinopathy-negative CM survivors were enrolled. Their neurologic outcomes were compared to 132 retinopathy-positive CM survivors and 272 controls. Compared to survivors of retinopathy-positive CM, children without malaria retinopathy have an equal odds of adverse neurologic outcome (odds ratio [OR] = 1.0, 95% confidence interval [CI] 0.4-2.2). Eleven of 35 survivors of retinopathy-negative CM had at least 1 adverse neurologic outcome compared to 2 of 272 controls (OR 61.9, 95% CI 13.0-295.5). In retinopathy-negative CM survivors, a Blantyre Coma Scale score ≤ 1 on admission was associated with an adverse outcome. CONCLUSIONS: Compared with controls, children surviving either retinopathy-negative or -positive CM are at similar high risk for adverse neurologic outcomes. Studies to evaluate preventive and therapeutic strategies in children with both retinopathy-negative and -positive CM are needed to improve mortality, morbidity, or both.
Authors: Nicholas A V Beare; Terrie E Taylor; Simon P Harding; Susan Lewallen; Malcolm E Molyneux Journal: Am J Trop Med Hyg Date: 2006-11 Impact factor: 2.345
Authors: Gretchen L Birbeck; Nicholas Beare; Susan Lewallen; Simon J Glover; Malcolm E Molyneux; Peter W Kaplan; Terrie E Taylor Journal: Am J Trop Med Hyg Date: 2010-02 Impact factor: 2.345
Authors: Gretchen L Birbeck; Malcolm E Molyneux; Peter W Kaplan; Karl B Seydel; Yamikani F Chimalizeni; Kondwani Kawaza; Terrie E Taylor Journal: Lancet Neurol Date: 2010-11-04 Impact factor: 44.182
Authors: Terrie E Taylor; Wenjiang J Fu; Richard A Carr; Richard O Whitten; Jeffrey S Mueller; Nedson G Fosiko; Susan Lewallen; N George Liomba; Malcolm E Molyneux; Jeffrey G Mueller Journal: Nat Med Date: 2004-01-25 Impact factor: 53.440
Authors: Rachel Brim; Sebastian Mboma; Margaret Semrud-Clikeman; Sam Kampondeni; Jed Magen; Terrie Taylor; John Langfitt Journal: Am J Trop Med Hyg Date: 2017-07 Impact factor: 2.345
Authors: Douglas G Postels; Gretchen L Birbeck; Clarissa Valim; Kara M Mannor; Terrie E Taylor Journal: Am J Trop Med Hyg Date: 2012-11-19 Impact factor: 2.345
Authors: Alexander Andrews; Tesfaye Zelleke; Rima Izem; Jiaxiang Gai; Dana Harrar; Jessica Mvula; Douglas G Postels Journal: Pediatr Neurol Date: 2021-10-19 Impact factor: 3.372
Authors: Paul Bangirana; Robert O Opoka; Michael J Boivin; Richard Idro; James S Hodges; Regilda A Romero; Elsa Shapiro; Chandy C John Journal: Clin Infect Dis Date: 2014-04-24 Impact factor: 9.079
Authors: Douglas G Postels; Chenxi Li; Gretchen L Birbeck; Terrie E Taylor; Karl B Seydel; Sam D Kampondeni; Simon J Glover; Michael J Potchen Journal: Am J Trop Med Hyg Date: 2014-09-08 Impact factor: 2.345
Authors: Gagandeep Singh; Samuel A Angwafor; Alfred K Njamnshi; Henry Fraimow; Josemir W Sander Journal: Nat Rev Neurol Date: 2020-05-19 Impact factor: 42.937
Authors: Douglas G Postels; Lawrence Osei-Tutu; Karl B Seydel; Qian Xu; Chenxi Li; Terrie E Taylor; Chandy C John; Macpherson Mallewa; Tom Solomon; Tsiri Agbenyega; Daniel Ansong; Robert O Opoka; Lillian M Khan; Prashanth S Ramachandran; Kristoffer E Leon; Joseph L DeRisi; Charles Langelier; Michael R Wilson Journal: Am J Trop Med Hyg Date: 2020-04-23 Impact factor: 2.345